证券代码：688278 证券简称：特宝生物 厦门特宝生物工程股份有限公司 简式权益变动报告书 上市公司名称：厦门特宝生物工程股份有限公司 信息披露义务人：通化东宝药业股份有限公司 公司住址/通讯地址：吉林省通化县东宝新村 股份变动性质：股份减少 签署日期：2025年5月22日 1 上市地点：上海证券交易所 股票简称：特宝生物 股票代码：688278 声 明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告 书》等相关法律、法规和规范性文件编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在厦门特宝生物工程股份有限公司拥有权益 的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通 过任何其他方式增加或减少其在厦门特宝生物工程股份有限公司中拥有权益的 股份。 四、本次权益变动是根据本报告书所载明的资料进 ...

特宝生物5月21日大宗交易平台共发生3笔成交，合计成交量33.00万股，成交金额2314.62万元。成交价 格均为70.14元。 进一步统计，近3个月内该股累计发生11笔大宗交易，合计成交金额为3.95亿元。 证券时报·数据宝统计显示，特宝生物今日收盘价为70.14元，下跌1.57%，日换手率为0.80%，成交额为 2.31亿元，全天主力资金净流入1502.38万元，近5日该股累计下跌4.06%，近5日资金合计净流入1.13亿 元。 两融数据显示，该股最新融资余额为8.54亿元，近5日增加1.24亿元，增幅为17.06%。（数据宝） 5月21日特宝生物大宗交易一览 | 成交量 （万 | 成交金额 （万元） | 成交价 格 | 相对当日收盘 折溢价（%） | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 股） | | （元） | | | | | 11.00 | 771.54 | 70.14 | 0.00 | 广发证券股份有限公司广州中 | 中信证券股份有限公 | | | | | | 山三路中华广场证券营业部 | 司总部(非营业场所) | | 11 ...

Core Viewpoint - The performance of listed companies in Xiamen demonstrates strong profitability and growth potential, contributing significantly to the stability of the regional economy, with 68 companies achieving a combined net profit of 3.816 billion yuan in Q1 2025 [2]. Group 1: Financial Performance - 68 listed companies in Xiamen reported a total net profit of 3.816 billion yuan in Q1 2025, with 62 companies profitable, representing over 90% [2]. - 38 companies experienced year-on-year profit growth, accounting for nearly 60% of the total [2]. - 17 companies reported profits exceeding 100 million yuan, highlighting the strong financial performance of the Xiamen market [2]. Group 2: Top Performing Companies - Xiamen Bank led with a net profit of 645 million yuan, with management expecting a gradual increase in return on investment (ROI) throughout the year [9]. - Jianfa Co. achieved a net profit of 584 million yuan, with total revenue reaching 143.773 billion yuan, a year-on-year increase of 9.47% [9]. - Yilian Network reported a net profit of 562 million yuan, with total revenue of 1.205 billion yuan, reflecting a year-on-year growth of 3.57% [9]. Group 3: Emerging Industries - Weike Technology's revenue reached 539 million yuan, a year-on-year increase of 64.37%, with net profit doubling to 77.3928 million yuan [11]. - Tebao Bio's revenue was 673 million yuan, up 23.48%, with a net profit of 182 million yuan, reflecting a 41.40% increase [12]. - Huamao Technology reported revenue of 537 million yuan, a 14.37% increase, with net profit rising by 60.34% to 86.4219 million yuan [12]. Group 4: Strategic Developments - Xiamen Xiangyu's net profit was 509 million yuan, a year-on-year increase of 24.88%, supported by improved risk management and financial structure [10]. - Companies are enhancing profitability through upstream and downstream integration and optimizing product structures, with Weike Technology focusing on high-performance precision molds for emerging industries [12].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688278 证券简称：特宝生物 公告编号：2025-018 厦门特宝生物工程股份有限公司 关于参加厦门辖区上市公司 2024 年年报业绩说明会 暨投资者网上集体接待日活动的公告 特此公告。 厦门特宝生物工程股份有限公司 董事会 2025 年 5 月 8 日 为进一步加强与投资者的互动交流，厦门特宝生物工程股份有限公司（以下 简称"公司"）将参加由厦门证监局、厦门上市公司协会与深圳市全景网络有限 公司联合举办的"厦门辖区上市公司 2024 年年报业绩说明会暨投资者网上集体 接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP 参与 本次互动交流，活动时间为 2025 年 5 月 15 日（周四）15:40-17:00。 公司董事长、总经理、董事会秘书、财务总监和独立董事将在线就公司 2024 年度业绩、公司治理、发展战略、经营状 ...

重要内容提示： 每股现金红利0.62元（含税） 本次利润分配方案经厦门特宝生物工程股份有限公司（以下简称"公司"）2025年4月18日的2024年年度 股东大会审议通过。 二、分配方案 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 3.分配方案： 本次利润分配以方案实施前的公司总股本406,800,000股为基数，每股派发现金红利0.62元（含税），共 计派发现金红利252,216,000元（含税）。 三、相关日期 ■ 四、分配实施办法 1.实施办法 除公司自行发放对象外，公司其余股东的红利委托中国结算上海分公司通过其资金清算系统向股权登记 日上海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定 交易的投资者可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中 国结算上海分公 ...

Investment Rating - The report indicates a cautious outlook for the pharmaceutical sector in 2024 and early 2025, with a strong focus on the innovative drug segment as a key investment opportunity [1][5]. Core Insights - The pharmaceutical sector is expected to face continued pressure on overall performance and profit margins due to factors such as healthcare payment environment, industry regulation, and changing consumer conditions in 2024 and Q1 2025 [1][18]. - Despite the challenges, there is optimism for a recovery in the pharmaceutical sector in the second half of 2025, driven by easing pressures from policies and fundamentals, leading to a potential turnaround in performance and stock prices [1][21]. - The innovative drug segment is highlighted as a primary focus for investment, with expectations for significant growth and valuation recovery for leading companies in this space [2][5]. Summary by Sections Pharmaceutical Sector Overview - The innovative drug segment is performing well, with leading companies like BeiGene and Hengrui Medicine showing strong revenue and business development (BD) income growth [2][22]. - The overall pharmaceutical sector is under pressure, with profit margins declining, except for the innovative drug segment which is experiencing independent growth [1][18]. Biopharmaceuticals - The biopharmaceutical sector is facing challenges, but there are opportunities for growth in specific areas such as long-acting interferons and insulin products, which are expected to see a turnaround [2][4]. Retail Pharmacy - The retail pharmacy sector is showing signs of marginal improvement, with expectations for a gradual return to normal growth in 2025 [2][4]. Medical Services and Aesthetic Medicine - The medical services and aesthetic medicine sectors are experiencing a mild recovery, with expectations for sustained performance in 2025 [3][4]. Traditional Chinese Medicine - The traditional Chinese medicine sector is expected to improve gradually throughout the year, following a challenging 2024 [4][12]. Medical Devices - The medical device sector is anticipated to recover gradually, with significant growth expected from overseas market expansion [4][12]. Investment Recommendations - The report emphasizes the importance of focusing on innovative drug opportunities throughout 2025, particularly in companies with strong international capabilities and those involved in business development [5][21].

证券代码：688278 证券简称：特宝生物 公告编号：2025-017 厦门特宝生物工程股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.62元（含税） 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/5/8 | 2025/5/9 | 2025/5/9 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经厦门特宝生物工程股份有限公司（以下简称"公司"） 2025 年 4 月 18 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本406,800,000股为基数，每股派发现 金红利0.62元（含税），共计派发现金红利25 ...

Core Viewpoint - Teabo Bio's performance continues to grow significantly in the hepatitis B field, with a strong increase in revenue and net profit in Q1 2025 compared to the previous year [1][2]. Financial Performance - In Q1 2025, Teabo Bio achieved revenue of 673 million yuan, a year-on-year increase of 23.48%, and a net profit of 182 million yuan, up 41.4% [1]. - From 2020 to 2024, the company's revenue grew from 794 million yuan to 2.817 billion yuan, while net profit increased from 117 million yuan to 828 million yuan [2]. - The company has maintained a continuous dual increase in revenue and net profit for seven consecutive years, with a cumulative net profit of 1.968 billion yuan since its IPO [2]. Product Development - The growth in performance is attributed to the stable sales of the key product, Peginterferon, which is a first-in-class drug with complete independent intellectual property rights [2]. - Teabo Bio has invested significantly in R&D, with expenditures rising from 76.68 million yuan in 2020 to 295 million yuan in 2024, totaling 833 million yuan over the five years [2]. Intellectual Property and Market Position - As of the end of 2024, Teabo Bio has obtained 16 invention patents and a total of 293 intellectual property rights [3]. - The company has made important progress in multiple R&D projects, including the acceptance of a drug registration application for its self-developed growth hormone injection in January 2024 [3]. Stock Performance - Teabo Bio's stock price has seen a significant increase, rising from an IPO price of 8.24 yuan per share to 78.96 yuan per share as of April 22, representing a cumulative increase of 858.25% [3].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥673,345,118.05, representing a 23.48% increase compared to ¥545,302,286.89 in the same period last year[3] - Net profit attributable to shareholders was ¥182,128,916.89, a 41.40% increase from ¥128,807,591.33 year-over-year[3] - Basic earnings per share increased by 40.63% to ¥0.45, compared to ¥0.32 in the same period last year[3] - Total operating revenue for Q1 2025 reached ¥673,345,118.05, a 23.5% increase from ¥545,302,286.89 in Q1 2024[16] - Net profit for Q1 2025 was ¥182,128,916.89, representing a 41.3% increase compared to ¥128,807,591.33 in Q1 2024[17] Cash Flow and Assets - The net cash flow from operating activities surged by 162.81%, amounting to ¥206,740,177.80, up from ¥78,663,848.24 in the previous year[3] - The company's cash and cash equivalents amounted to RMB 528,072,404.71, up from RMB 371,821,698.43, indicating a significant increase of about 42.03%[12] - Total assets at the end of the reporting period were ¥3,179,123,636.38, a 4.22% increase from ¥3,050,414,835.58 at the end of the previous year[4] - The total assets of the company rose to ¥3,179,123,636.38 in Q1 2025 from ¥3,050,414,835.58 in Q1 2024, marking an increase of 4.2%[15] - The company reported a cash outflow of CNY 614,579,315.86 from operating activities, which is an increase from CNY 550,264,204.09 in the previous year[19] Research and Development - Research and development expenses totaled ¥77,188,385.02, marking a 38.77% increase from ¥55,622,956.59 in the previous year, accounting for 11.46% of operating revenue[3] - Research and development expenses for Q1 2025 were ¥66,748,824.30, up 53.3% from ¥43,575,928.52 in Q1 2024, indicating a strong focus on innovation[16] Shareholder Information - The company reported a total of 7,468 common shareholders at the end of the reporting period[6] - The top shareholder, Yang Ying, holds 33.94% of the shares, totaling 138,077,266 shares[7] Community and Health Initiatives - The company has committed to additional donations totaling RMB 8 million for various hepatitis-related projects, with RMB 4 million already disbursed by the end of the reporting period[9] - The company has also donated RMB 2.7 million for the "Oasis Project" aimed at reducing liver cancer incidence among hepatitis patients, with total donations reaching RMB 31 million by the end of the reporting period[10] - The company plans to continue its support for hepatitis research and treatment initiatives, with ongoing projects and additional funding commitments[11] - The company is actively involved in community health initiatives, contributing to various projects aimed at improving public health outcomes related to hepatitis[9] Liabilities and Equity - Total liabilities decreased to ¥429,839,424.62 in Q1 2025 from ¥497,098,543.83 in Q1 2024, a reduction of approximately 13.5%[14] - Total equity attributable to shareholders increased to ¥2,749,284,211.76 in Q1 2025 from ¥2,553,316,291.75 in Q1 2024, reflecting a growth of 7.7%[15] Inventory and Receivables - Accounts receivable decreased to RMB 654,023,595.24 from RMB 771,496,539.39, representing a decline of approximately 15.19%[12] - Inventory increased to RMB 285,459,731.42 from RMB 263,546,426.51, showing a growth of about 8.29%[13] Financial Management - The company reported a financial asset impairment loss of ¥779,811.54 in Q1 2025, compared to ¥127,378.79 in Q1 2024, highlighting increased caution in asset management[17] - Deferred income increased to ¥40,555,586.47 in Q1 2025 from ¥32,961,392.76 in Q1 2024, indicating growth in future revenue recognition[14]

厦门特宝生物工程股份有限公司 2024 年年度股东大会的 法律意见书 上海市锦天城（深圳）律师事务所 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 关于 上海市锦天城（深圳）律师事务所 法律意见书 关于厦门特宝生物工程股份有限公司 2024 年年度股东大会的 上海市锦天城（深圳）律师事务所 法律意见书 致：厦门特宝生物工程股份有限公司 根据厦门特宝生物工程股份有限公司（以下简称"贵公司"或者"公司"） 的委托，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）等法律、行政法规以及《厦 门特宝生物工程股份有限公司章程》（以下简称"《公司章程》"）、《厦门特 宝生物工程股份有限公司股东大会议事规则》（以下简称"《股东大会议事规 则》"）的规定，上海市锦天城（深圳）律师事务所（以下简称"本所"）指派 律师列席了公司 2024 年年度股东大会（以下简称"本次股东大会"），现就公 司本次股东大会召开的有关事宜出具本法律意见书。 本所同意将本法律意见书随贵公司本次股东大会 ...